It was hypothesized that the effect of pioglitazone on promoting bladder cancer might be due to its PPARα activity [18], as this was not observed with rosiglitazone, which is highly selective for PPARγ [19]. The gene discussed is PPARA; the disease is urinary bladder carcinoma.